title: Circulating microRNAs as potential new biomarkers for prostate cancer.
abstract: Since they were first described in the 1990s, circulating microRNAs (miRNAs) have provided an active and rapidly evolving area of current research that has the potential to transform cancer diagnostics and therapeutics. In particular, miRNAs could provide potential new biomarkers for prostate cancer, the most common cause of cancer in UK men. Current diagnostic tests for prostate cancer have low specificity and poor sensitivity. Further, although many prostate cancers are so slow growing as not to pose a major risk to health, there is currently no test to distinguish between these and cancers that will become aggressive and life threatening. Circulating miRNAs are highly stable and are both detectable and quantifiable in a range of accessible bio fluids, thus have the potential to be useful diagnostic, prognostic and predictive biomarkers. This review aims to summarise the current understanding of circulating miRNAs in prostate cancer patients and their potential role as biomarkers.
authors: Androgen Signalling Laboratory, Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK.
authors: A
authors: A
authors: Sita-Lumsden
authors: D A
authors: DA
authors: Dart
authors: J
authors: J
authors: Waxman
authors: C L
authors: CL
authors: Bevan
mesh_terms: D001692:Biological Transport / Q000502:physiology; D014408:Biomarkers, Tumor / Q000097:blood*; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D058990:Molecular Targeted Therapy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs
references: Clin Cancer Res. 2008 Oct 1;14(19):6302-9
references: 18829513
references: Prostate. 2011 Feb 15;71(3):326-31
references: 20842666
references: J Urol. 2007 Nov;178(5):1957-62; discussion 1962
references: 17868719
references: Commun Integr Biol. 2010 Sep;3(5):478-81
references: 21057646
references: Int J Cancer. 2011 Feb 1;128(3):608-16
references: 20473869
references: Tumour Biol. 2011 Jun;32(3):583-8
references: 21274675
references: Prostate. 2012 Sep 15;72(13):1469-77
references: 22298119
references: Curr Opin Urol. 2009 May;19(3):227-31
references: 19357513
references: Urology. 2011 May;77(5):1265.e9-16
references: 21539977
references: Methods. 2010 Apr;50(4):298-301
references: 20146939
references: Hum Mol Genet. 2012 Jul 15;21(14):3112-27
references: 22505583
references: Prostate. 2012 Sep 15;72(13):1443-52
references: 22298030
references: Nat Genet. 2003 Nov;35(3):215-7
references: 14528307
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D152-7
references: 21037258
references: Br J Cancer. 2012 Feb 14;106(4):768-74
references: 22240788
references: J Urol. 2005 Jun;173(6):1938-42
references: 15879786
references: Int J Cancer. 2012 Aug 1;131(3):652-61
references: 22052531
references: Nat Rev Cancer. 2009 Apr;9(4):293-302
references: 19262572
references: Curr Opin Pharmacol. 2010 Oct;10(5):543-50
references: 20541466
references: Clin Genitourin Cancer. 2011 Sep;9(1):39-45
references: 21723797
references: J Urol. 2004 Jun;171(6 Pt 1):2255-9
references: 15126797
references: Nat Rev Clin Oncol. 2011 Jun 07;8(8):467-77
references: 21647195
references: Cancer Lett. 2009 Jan 18;273(2):233-42
references: 18789835
references: Gynecol Oncol. 2008 Jul;110(1):13-21
references: 18589210
references: Expert Rev Mol Diagn. 2011 Apr;11(3):249-57
references: 21463235
references: Prostate. 2011 May;71(6):604-14
references: 20945501
references: PLoS One. 2009 Jul 14;4(7):e6229
references: 19597549
references: Cell Res. 2008 Oct;18(10):997-1006
references: 18766170
references: PLoS One. 2010 Oct 20;5(10):e13515
references: 20976003
references: Cancer Res. 2011 Jan 15;71(2):550-60
references: 21098088
references: Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
references: 18663219
references: Mol Cancer Res. 2011 Jun;9(6):791-800
references: 21593139